MyFinsight
Home
Blog
About
Tempest Therapeutics, Inc. (TPST)
Tempest Therapeutics, Inc. (TPST)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$1,026K
Free Cash flow
-$2,779K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Research and development expense...
Accounts payable
Others
Negative Cash Flow Breakdown
Net loss
Accrued expenses and other liabi...
Operating lease liabilities
Prepaid expenses and other asset...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-5,244
-27,696
-4,021
-3,511
Depreciation expense
60
60
65
66
Stock-based compensation expense
-117
226
576
61
Non-cash lease expense
299
292
285
279
Non-cash interest and other expense, net
0
0
8
1
Research and development expense funded by related party contribution of services
1,710
-
-
-
Acquired in-process research and development
0
19,927
-
-
Prepaid expenses and other assets
269
71
-33
-243
Accounts payable
1,411
-454
116
-3,794
Accrued expenses and other liabilities
-335
405
-372
134
Interest payable
0
0
0
0
Operating lease liabilities
-294
-287
-264
-258
Cash used in operating activities
-2,779
-7,598
-3,574
-6,779
Purchase of property and equipment
0
0
0
0
Cash used in investing activities
0
0
0
0
Proceeds from the issuance of common stock, net of issuance costs
-
-
1,032
0
Proceeds from the issuance of pre-funded warrants, net of issuance costs
-
-
1,451
0
Proceeds from issuance of common stock, pre-funded warrants and common stock warrants, net of issuance costs
1,753
1,272
-
-
Proceeds from the issuance of common stock warrants, net of issuance costs
-
-
1,284
-
Proceeds from the issuance of common stock and common stock warrants to related party, net of issuance costs
0
424
-
-
Repayment of loan
0
0
0
0
Proceeds from the issuance of common stock under equity plan awards
0
0
0
13
Cash provided by financing activities
1,753
1,696
3,767
13
Net decrease in cash, cash equivalents and restricted cash
-1,026
-5,902
193
-6,766
Cash, cash equivalents and restricted cash at beginning of period
2,248
8,150
7,957
30,711
Cash, cash equivalents and restricted cash at end of period
1,222
2,248
8,150
7,957
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock,...
$1,753K
Cash provided by
financing activities
$1,753K
(265.97%↑ Y/Y)
Net decrease in
cash, cash...
-$1,026K
(93.58%↑ Y/Y)
Canceled cashflow
$1,753K
Research and development
expense funded by...
$1,710K
Accounts payable
$1,411K
(-37.73%↓ Y/Y)
Non-cash lease expense
$299K
(-44.53%↓ Y/Y)
Depreciation expense
$60K
(-55.56%↓ Y/Y)
Cash used in
operating activities
-$2,779K
(83.12%↑ Y/Y)
Canceled cashflow
$3,480K
Net loss
-$5,244K
(72.00%↑ Y/Y)
Accrued expenses and
other liabilities
-$335K
(89.42%↑ Y/Y)
Operating lease
liabilities
-$294K
(15.52%↑ Y/Y)
Prepaid expenses and
other assets
$269K
(179.35%↑ Y/Y)
Stock-based compensation
expense
-$117K
(-104.72%↓ Y/Y)
Buy us a coffee